Pharmaceuticals

M&A Roundup 2024: Q&A with Subin Baral

bexib
By bexib 0 Min Read

EY Global Life Sciences deals leaders discuss how the first half of 2024 performed compared to a strong end to 2023.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Survey shows most retail brands are ignoring X
Next Article Review: AnyCubic Kobra 3 – Manufacturer:
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Upskilling: An interview with Steph Piper
Manufacturing
Young Kiwis toast change: hazardous drinking falls by 13% in five years
Hospitality & Tourism
Clearview FCU saves 6,000 labor hours through RPA
Banking
Inside Varo Bank’s GEN AI Copilot build
Banking